The Frustrating Business Tactic of Pay for Delay by Big Pharma
Antiretroviral drugs have revolutionized the treatment of HIV/AIDS, but their high costs continue to be a barrier for many patients. One factor contributing to these high prices is the exclusion of generic competition through “pay for delay” agreements. Brand-name drug companies pay other companies to delay the introduction of generic equivalents, allowing them to maintain …